Momentum in Motion

Latest updates, partnerships, and breakthroughs from Aviva Bio

Hormone therapy is undergoing cultural and regulatory re-evaluation, while metabolic medicine and women’s health represent major growth frontiers. d3-T sits at the intersection of these shifts.

Press Releases

Aviva Bio Announces FDA Guidance on Development Pathway for Women’s Testosterone Therapy and New Evidence of a Reduced Risk of Breast Cancer Cell Proliferation for AVA-291

Jan 26, 2026 — In its feedback, the FDA acknowledged the potential breast cancer risk associated with T use in women—a central safety issue that has historically limited the development of a T therapy for women. Read more.

Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025

Jul 14, 2025 — d3-T is a novel, non-aromatizing androgen, offering the benefits of testosterone without converting to estradiol, addressing a known breast cancer risk. Read more.

Aviva Bio Launches to Transform Hormone-Based Medicine— Starting with Women

May 6, 2025 — Aviva Biopharm Inc., a clinical-stage biotech company, launches this month with a mission to rewrite the future of hormone-based medicine. With its lead asset, AVA-291 (d3-Testosterone), Aviva Bio is targeting a long-overlooked need in healthcare: an FDA-approved testosterone therapy for women. Read more.

Events

Won Women’s Health Week USA 2026 Therapeutics & Medical Devices Pitch Competition

From a record 170 applications, 15 companies were selected to pitch on the main stage at Women’s Health Week USA 2026. Aviva-Bio took top honors as the winner of the competition! Head of Business Development Jessica Halem is pictured below, presenting the winning pitch.

Presented at AACR Annual Meeting 2026

Aviva Bio presented their poster abstract titled “Effects of AVA-291 (d3-testosterone) versus testosterone on MCF-7 estrogen receptor positive breast cancer cells – lack of aromatization to estradiol leads to a highly differentiated cellular proliferation profile” on April 20, 2026 at AACR 2026 in San Diego.

Review the poster here.

Presented at ENDO 2025

Aviva Bio presented their poster abstract titled “Characterization of d3-Testosterone, A Novel, Non-Aromatizing Androgen” on July 14, 2025 at Endo 2025 in San Francisco. Review the poster here.